Veliparib

Generic Name: Veliparib

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₁₆N_₄O

CAS Number: 912444-00-9

Unique Ingredient Identifier: 01O4K0631N

Indication: 与化疗药物紫杉醇和卡铂联合用于治疗乳腺癌。

Clinical Trials

FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

Phase 2

Active, not recruiting

Conditions: Metastatic Pancreatic Adenocarcinoma
Recurrent Pancreatic Carcinoma
Stage IV Pancreatic Cancer AJCC v6 and v7

Interventions: Drug: Fluorouracil
Drug: Irinotecan Hydrochloride
Other: Laboratory Biomarker Analysis
Drug: Leucovorin Calcium
Drug: Veliparib

First Posted Date: 2016-09-07

Last Posted Date: 2025-05-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 123

Registration Number: NCT02890355

Locations: 🇺🇸
University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States
🇺🇸
Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
🇺🇸
Anchorage Radiation Therapy Center, Anchorage, Alaska, United States

and more 779 locations

Study of Gemcitabine, Carboplatin and VELIPARIB (ABT-888) in Refractory Testicular Germ Cell Cancer

Phase 2

Completed

Conditions: Testicular Cancer

Interventions: Drug: Veliparib
Drug: Gemcitabine
Drug: Carboplatin

First Posted Date: 2016-08-09

Last Posted Date: 2021-03-03

Lead Sponsor: National Cancer Institute, Slovakia

Target Recruit Count: 15

Registration Number: NCT02860819

Locations: 🇸🇰
National Cancer Institute, Bratislava, Slovakia

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

Phase 1

Withdrawn

Conditions: Multiple Endocrine Neoplasia Type 1
Functional Pancreatic Neuroendocrine Tumor
Malignant Somatostatinoma
Metastatic Carcinoid Tumor
Multiple Endocrine Neoplasia Type 2A
Stage IIIA Merkel Cell Carcinoma
Stage IIIB Merkel Cell Carcinoma
Stage IVB Thyroid Gland Medullary Carcinoma
VIP-Producing Neuroendocrine Tumor
Merkel Cell Carcinoma

Interventions: Drug: Capecitabine
Drug: Temozolomide
Drug: Veliparib
Other: Pharmacological Study
Other: Laboratory Biomarker Analysis

First Posted Date: 2016-07-13

Last Posted Date: 2017-09-28

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Registration Number: NCT02831179

Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: Veliparib + VX-970 + Cisplatin

First Posted Date: 2016-03-31

Last Posted Date: 2022-02-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 53

Registration Number: NCT02723864

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors

Phase 1

Completed

Conditions: Malignant Solid Neoplasm

Interventions: Drug: Ferumoxytol
Drug: Irinotecan Sucrosofate
Other: Laboratory Biomarker Analysis
Procedure: Magnetic Resonance Imaging
Drug: Veliparib

First Posted Date: 2015-12-16

Last Posted Date: 2025-02-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 18

Registration Number: NCT02631733

Locations: 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸
NCI - Center for Cancer Research, Bethesda, Maryland, United States
🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

and more 3 locations

Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases

Phase 2

Completed

Conditions: Metastatic Breast Carcinoma
Metastatic Malignant Neoplasm in the Brain
Metastatic BRCA Hereditary Breast Carcinoma
Metastatic Triple-Negative Breast Carcinoma
Recurrent Breast Carcinoma
Stage IV Breast Cancer AJCC v6 and v7

Interventions: Drug: Cisplatin
Other: Laboratory Biomarker Analysis
Other: Placebo Administration
Drug: Veliparib

First Posted Date: 2015-11-04

Last Posted Date: 2025-05-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 344

Registration Number: NCT02595905

Locations: 🇺🇸
Mountain Blue Cancer Care Center, Golden, Colorado, United States
🇺🇸
UCHealth University of Colorado Hospital, Aurora, Colorado, United States
🇺🇸
Boulder Community Hospital, Boulder, Colorado, United States

and more 803 locations

Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer

Phase 1

Completed

Conditions: Ovarian Cancer

Interventions: Drug: veliparib
Drug: carboplatin
Drug: paclitaxel

First Posted Date: 2015-06-26

Last Posted Date: 2017-11-20

Lead Sponsor: AbbVie

Target Recruit Count: 9

Registration Number: NCT02483104

Locations: 🇯🇵
Site Reference ID/Investigator# 128815, Kurume-shi,Fukuoka, Japan
🇯🇵
Site Reference ID/Investigator# 128058, Nagaizumi-cho, Japan
🇯🇵
Site Reference ID/Investigator# 128997, Morioka-shi, Japan

Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 3

Terminated

Conditions: Ovarian Cancer
Ovarian Neoplasm

Interventions: Drug: Paclitaxel
Drug: Veliparib
Drug: Carboplatin
Other: Placebo to Veliparib

First Posted Date: 2015-06-12

Last Posted Date: 2024-10-26

Lead Sponsor: AbbVie

Target Recruit Count: 1140

Registration Number: NCT02470585

Locations: 🇺🇸
Sinai Hospital of Baltimore /ID# 141306, Baltimore, Maryland, United States
🇺🇸
The Ohio State University - Columbus /ID# 138053, Columbus, Ohio, United States
🇺🇸
Fox Chase Cancer Center /ID# 149479, Philadelphia, Pennsylvania, United States

and more 207 locations

A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC)

Phase 1

Terminated

Conditions: Non-small Cell Lung Cancer Stage III

Interventions: Drug: Paclitaxel
Drug: Placebo for Veliparib
Drug: Carboplatin
Drug: Veliparib
Radiation: Radiotherapy

First Posted Date: 2015-04-09

Last Posted Date: 2020-07-22

Lead Sponsor: AbbVie

Target Recruit Count: 48

Registration Number: NCT02412371

Locations: 🇺🇸
Rhode Island Hospital /ID# 133493, Providence, Rhode Island, United States
🇺🇸
Univ Maryland School Medicine /ID# 132944, Baltimore, Maryland, United States
🇺🇸
Dana-Farber Cancer Institute /ID# 133494, Boston, Massachusetts, United States

and more 9 locations

Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Untreated Metastatic Colorectal Cancer

Interventions: Drug: Placebo
Drug: Veliparib
Drug: FOLFIRI
Drug: Modified FOLFIRI
Drug: Bevacizumab
Drug: Fluorouracil infusion

First Posted Date: 2014-12-03

Last Posted Date: 2018-11-20

Lead Sponsor: AbbVie

Target Recruit Count: 130

Registration Number: NCT02305758

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy